A lot is happening across the MIB community as we head into an exciting season of connection, innovation, and impact. We are excited to spotlight Carey Bringle, osteosarcoma survivor and founder of Peg Leg Porker. Registration is now open for our 9th Annual FACTOR conference this June in Columbus, where we’ll once again bring together our community for a powerful few days of learning and collaboration—including Ambassador Agent training opportunities. As we look ahead, we’re also gearing up for MIB Agents Day of Giving on May 1, 2026, marking 10 years of Making It Better and fueling the next decade of progress. New opportunities, such as SARC’s Brian Van Tine Early Career Travel Awards, are supporting rising leaders, while promising research continues to advance, including a newly opened Phase 1/2 clinical trial at UCLA.
With hope,
The MIB Agents Team
.png)
This month, we’re spotlighting Carey Bringle, founder of Peg Leg Porker and a resilient osteosarcoma survivor. Carey’s story is one of turning adversity into a legacy. He joins us to reflect on his journey through childhood cancer and limb loss, exploring how those experiences continue to inspire his work and his commitment to the osteosarcoma community through MIB Agents.
Learn More About Carey Bringle
.png)
Each year, the MIB Agents FACTOR Conference brings together a dedicated community of researchers, clinicians, surgeons, patient families, and OsteoWarriors — all connected by a shared commitment to improving the lives of those affected by osteosarcoma. Rooted in Funding, Awareness, Collaboration, Trials, Osteosarcoma, and Research, FACTOR is designed to foster meaningful connections, fuel innovation, and move the field forward. We hope you’ll join us this June in Columbus for our 9th Annual FACTOR Conference!
.png)
On May 1, 2026, join us for MIB Agents Day of Giving as we celebrate 10 years of Making It Better for kids, families, and the osteosarcoma community. This special milestone is a chance to honor how far we’ve come together — and to power the next decade of hope, research, and support.
Stay tuned for inspiring stories, meaningful ways to give, and opportunities to be part of this mission-driven day of impact.
Let’s make our 10th anniversary one to remember!
If you have a job posting and you would like it included here, please email christina@mibagents.org.
The Sarcoma Alliance for Research through Collaboration (SARC) is investing in the next generation of sarcoma leaders through the Brian Van Tine Early Career Travel Awards. These awards provide up to $1,000 to help trainees and early-career investigators attend key scientific meetings, fostering collaboration, mentorship, and innovation in the field.
Established in honor of Dr. Brian Van Tine’s legacy of collaboration and mentorship, the awards reflect a shared commitment to fostering innovation and supporting rising talent.
Applications are open on a rolling basis, and early funding priorities include SASS, SASS-y, Sarcoma P31, and the SARCH semiannual meetings held before ASCO and during CTOS.
What topics would you like to see covered on the osTEAo AYA podcast? Whether it’s conversations around navigating treatment, life after diagnosis, or anything in between, your ideas help shape meaningful episodes for our community.
If you haven’t tuned in yet, now’s a great time to listen - osTEAo features honest, real conversations from AYA voices that inform, connect, and remind you that you’re not alone.
.png)
Learn More About Ambassador Agents
A Phase 1/2 clinical trial has just opened at UCLA for relapsed/refractory osteosarcoma. This study is evaluating LNTH-2403, a humanized monoclonal antibody called DUNP19 that is linked to lutetium-177 (¹⁷⁷Lu), a radioactive isotope. DUNP19 is designed to specifically target LRRC15, a protein highly expressed on osteosarcoma tumor cells and surrounding tumor-supporting cells in the microenvironment, but minimally present in healthy tissues. Once bound to LRRC15-expressing cells, the attached ¹⁷⁷Lu delivers targeted therapeutic radiation directly to the tumor and surrounding stromal cells in the tumor microenvironment. The study sponsor is offering financial assistance for patients to travel to UCLA.
To learn more about the study, watch David Ulmert discuss the preclinical rationale for this study on OsteoBites. Register for OsteoBites on May 14 for an overview of the clinical trial presented by one of the study investigators, Dr. David Shulman at Dana-Farber Cancer Institute. For more information, contact Gregory Ellis at UCLA at (424) 320-1853 or GEllis@mednet.ucla.edu.
.png)
